Nephros, Inc. (NEPH) P/E Ratio History
Deep ValueTrading at 28.6x · 17th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Nephros, Inc. (NEPH) trades at a price-to-earnings ratio of 28.6x, with a stock price of $3.15 and trailing twelve-month earnings per share of $0.07.
The current P/E is 56% below its 5-year average of 65.4x. Over the past five years, NEPH's P/E has ranged from a low of 22.8x to a high of 216.2x, placing the current valuation at the 17th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, NEPH trades at a 29% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, NEPH trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NEPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NEPH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NEPH P/E vs Peers
Wound care and infection prevention peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 21.6Lowest | 0.59Best | -65% | |
| $5B | 32.1 | 3.68 | -16% | |
| $478M | 26.2 | 1.97 | -36% | |
| $125B | 35.2 | - | -5% | |
| $12B | 70.2 | - | +1156%Best | |
| $23B | 33.0 | 6.38 | +0% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NEPH Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $2.98 | $0.07 | 42.2x | -35% |
| FY2025 Q4 | Dec 31 2025 | $4.88 | $0.11 | 44.2x | -32% |
| FY2025 Q3 | - | $4.73 | $0.14 | 34.3x | -48% |
| FY2025 Q2 | Jun 30 2025 | $4.09 | $0.12 | 32.7x | -50% |
| FY2025 Q1 | Mar 31 2025 | $1.72 | $0.08 | 22.8x | -65% |
| FY2024 Q4 | - | $1.47 | $0.01 | 216.2x | +231% |
Average P/E for displayed period: 65.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NEPH — Frequently Asked Questions
Quick answers to the most common questions about buying NEPH stock.
What is NEPH's P/E ratio?
Nephros, Inc. (NEPH) trailing twelve-month P/E ratio is 28.6x, based on TTM diluted EPS of $0.07. The 5-year average P/E is 65.4x and the historical range spans 22.8x to 216.2x.
Is NEPH stock overvalued or undervalued?
NEPH trades at 28.6x P/E, below its 5-year average of 65.4x. At the 17th percentile of its historical range (22.8x–216.2x), the stock is priced at a discount to its own history.
Is NEPH stock expensive?
No, NEPH is not expensive on a historical basis. The current P/E of 28.6x is below the 5-year average of 65.4x and sits at the 17th percentile of its valuation range.
What is NEPH's historical P/E range?
Over the past 5 years, NEPH's P/E ratio has ranged from 22.8x to 216.2x, with a median of 42.2x and an average of 65.4x. The current P/E of 28.6x places the stock at the 17th percentile of this range. Full historical data spans 2024–2026.
How does NEPH's P/E compare to the S&P 500?
NEPH trades at 28.6x P/E versus the S&P 500 median of 24.4x. The 17% premium to the market typically reflects higher expected earnings growth or quality.
How does NEPH's valuation compare to Healthcare peers?
Nephros, Inc. P/E of 28.6x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NEPH's PEG ratio?
NEPH PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NEPH's earnings yield?
NEPH earnings yield is 3.49%, the inverse of its 28.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.